- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07450547
ANG003의 안전성과 유효성을 평가하기 위한 2상 연구
낭포성 섬유증으로 인한 외분비 췌장 기능 부전 환자에서 두 가지 다른 용량 수준의 ANG003의 안전성 및 유효성을 평가하기 위한 2상, 다기관, 무작위, 능동 대조군 연구
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
연구 개요
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Evan Bailey, MD
- 전화번호: 617-466-3111
- 이메일: medical@anagramtx.com
연구 장소
-
-
California
-
Long Beach, California, 미국, 90806
- 모병
- Long Beach Memorial Medical Center
-
연락하다:
- Angelica Rodriguez
- 전화번호: 562-706-1245
- 이메일: ARodriguez9@memorialcare.org
-
Los Angeles, California, 미국, 90033
- 모병
- Center for Cystic Fibrosis at Keck Medical Center of USC
-
연락하다:
- Lynn Fukushima
- 전화번호: 323-442-8522
- 이메일: lynn.fukushima@med.usc.edu
-
-
Colorado
-
Denver, Colorado, 미국, 80206
- 모병
- National Jewish Health
-
연락하다:
- Alix Wilson
- 전화번호: 303-270-2517
- 이메일: wilsona@njhealth.org
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- 아직 모집하지 않음
- University of Florida
-
연락하다:
- Alexa Smith
- 전화번호: 352-273-8380
- 이메일: alexa.howell@ufl.edu
-
Orlando, Florida, 미국, 32803
- 아직 모집하지 않음
- Central Florida Pulmonary Group
-
연락하다:
- Desiree Serr
- 전화번호: 407-303-7192
- 이메일: desiree.serr1@adventhealth.com
-
-
Georgia
-
Atlanta, Georgia, 미국, 30324
- 모병
- Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
-
연락하다:
- Eric Hunter
- 전화번호: 678-977-5212
- 이메일: eahunte@emory.edu
-
-
Illinois
-
Glenview, Illinois, 미국, 60025
- 모병
- The Cystic Fibrosis Institute
-
연락하다:
- Steven R Boas, MD
- 전화번호: 847-998-3434
- 이메일: sboas@wecare4lungs.com
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 아직 모집하지 않음
- University of Iowa
-
연락하다:
- Mary Teresi
- 전화번호: 319-384-7546
- 이메일: mary-teresi@uiowa.edu
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 모병
- University of Kansas Medical Center
-
연락하다:
- Lawrence Scott
- 전화번호: 913-588-4020
- 이메일: lscott2@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40506
- 모병
- University of Kentucky
-
연락하다:
- Chase Whitaker
- 전화번호: 859-218-4810
- 이메일: chase.whitaker@uky.edu
-
-
Maine
-
Portland, Maine, 미국, 04102
- 아직 모집하지 않음
- MaineHealth Pediatric Specialty Care
-
연락하다:
- Rebecca Edwards
- 전화번호: 207-662-6712
- 이메일: rebecca.edwards@mainehealth.org
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital
-
연락하다:
- Margot Hardcastle
- 전화번호: 617-726-3719
- 이메일: mhardcastle@mgh.harvard.edu
-
Boston, Massachusetts, 미국, 02115
- 모병
- Boston Children's Hospita
-
연락하다:
- Robert Fowler
- 전화번호: 617-355-1834
- 이메일: Robert.fowler@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan, Michigan Medicine
-
연락하다:
- Dawn Kruse
- 전화번호: 734-615-3266
- 이메일: dmkruse@med.umich.edu
-
Detroit, Michigan, 미국, 48201
- 모병
- Wayne State University Harper University Hospital
-
연락하다:
- Debra Driscoll
- 전화번호: 313-745-2221
- 이메일: ddriscol@med.wayne.edu
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University of Minnesota
-
연락하다:
- Brooke Noren, RN, BSN, CCRC
- 전화번호: 612-625-7995
- 이메일: boer0039@umn.edu
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers - Robert Wood Johnson Medical School
-
연락하다:
- Sheila Redding
- 전화번호: 732-235-7840
- 이메일: sr1238@rwjms.rutgers.edu
-
-
New York
-
Valhalla, New York, 미국, 10595
- 아직 모집하지 않음
- New York Medical College at Westchester Medical Center
-
연락하다:
- Zachary Messer
- 전화번호: 914-594-2352
- 이메일: Zachary_Messer@nymc.edu
-
-
Ohio
-
Akron, Ohio, 미국, 44308
- 모병
- Children's Hospital Medical Center of Akron
-
연락하다:
- Michelle Parrish
- 전화번호: 330-543-3089
- 이메일: MParrish@akronchildrens.org
-
Cleveland, Ohio, 미국, 44106
- 모병
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
-
연락하다:
- Primary RC & Participant Contact General Contact
- 전화번호: 216-844-3911
- 이메일: RainbowCFResearch@UHhospitals.org
-
Columbus, Ohio, 미국, 43205
- 모병
- Nationwide Children's Hospital, Columbus
-
연락하다:
- Diana Gilmore
- 전화번호: 614-722-4752
- 이메일: diana.gilmore@nationwidechildrens.org
-
Toledo, Ohio, 미국, 43606
- 모병
- Toledo Children's Hospital
-
연락하다:
- Kelly Hoot
- 전화번호: 419-291-4630
- 이메일: kelly.hoot@promedica.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Hershey Medical Center Pennsylvania State University
-
연락하다:
- Diane Kitch
- 전화번호: 717-531-5646
- 이메일: dkitch@pennstatehealth.psu.edu
-
Pittsburgh, Pennsylvania, 미국, 15224
- 아직 모집하지 않음
- University of Pittsburgh Medical Center
-
연락하다:
- Adrienne DeRicco
- 전화번호: 412-692-8069
- 이메일: adrienne.dericco2@upmc.edu
-
-
Texas
-
Dallas, Texas, 미국, 75207
- 모병
- University of Texas Southwestern / Children's Health
-
연락하다:
- Keianna Brown
- 전화번호: 214-456-5489
- 이메일: Keianna.brown@utsouthwestern.edu
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- 모병
- Adult Cystic Fibrosis Center at the University of Utah
-
연락하다:
- Kristyn Packer
- 전화번호: 801-520-5106
- 이메일: kristyn.packer@hsc.utah.edu
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- 모병
- University of Wisconsin
-
연락하다:
- Melanie Nelson
- 전화번호: 608-265-4617
- 이메일: mnelson@pediatrics.wisc.edu
-
Milwaukee, Wisconsin, 미국, 53226
- 아직 모집하지 않음
- Froedtert & Medical College of Wisconsin
-
연락하다:
- Erin Hubertz
- 전화번호: 414-955-7019
- 이메일: ehubertz@mcw.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU
-
Confirmed and documented diagnosis of CF
-
Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.
-
Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.
-
Adequate nutritional status measured by body mass index (BMI) defined by:
- BMI ≥25th percentile for children aged 12-17 years
- BMI ≥18.5 kg/m2 for ≥18 years of age
Exclusion Criteria:
- History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
- History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
- Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
- Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ANG003 Dose A
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis. |
160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
실험적: ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
|
활성 비교기: Creon
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis. |
The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction. |
|
간섭 없음: Off Enzyme
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days. |
|
|
다른: 60% to <80% CFA ANG003 Dose B
All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B. |
240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP]) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
기간: From Visit 1 to Visit 5, anticipated average 80 days
|
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values |
From Visit 1 to Visit 5, anticipated average 80 days
|
|
Coefficient of Fat Absorption (CFA)
기간: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CFA collection
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
기간: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
|
|
Coefficient of Nitrogen Absorption (CNA)
기간: Period A (baseline) and Period B 72 hour CNA collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour CNA collection
|
|
% of subjects with GI symptoms
기간: From Visit 2 to Visit 5, anticipated average 59 days
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
From Visit 2 to Visit 5, anticipated average 59 days
|
|
Cumulative stool weight
기간: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
|
Number of Stools per Day
기간: Period A (baseline) and Period B 72 hour collection
|
Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%. |
Period A (baseline) and Period B 72 hour collection
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Correlation between DHA/EPA and CFA
기간: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
Mean change from baseline for each treatment group with a baseline CFA ≥80% |
Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
|
|
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
기간: Period A (baseline) and Period B 72 hour CFA collection
|
Mean change from baseline for each treatment group with a baseline CFA 60% to <80% |
Period A (baseline) and Period B 72 hour CFA collection
|
|
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
기간: Period B 72 hour CFA collection
|
Period B CFA Off Enzyme in subjects with a baseline CFA ≥80% |
Period B 72 hour CFA collection
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- ANG003-25-201
- 2025-524569-25-00 (씨티스)
- 2025 (미국 NIH 보조금/계약)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .